Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
Open Access
- 4 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1), 1-18
- https://doi.org/10.1186/s13046-021-01856-3
Abstract
Background: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with high proliferative activity. TNBC tumors exhibit elevated MYC expression and altered expression of MYC regulatory genes, which are associated with tumor progression and poor prognosis; however, the underlying mechanisms by which MYC retains its high expression and mediates TNBC tumorigenesis require further exploration. Methods: ACTL6A regulation of MYC and its target gene, CDK2, was defined using Co-IP, mass spectrometry and ChIP assays. To study the role of ACTL6A in TNBC, we performed soft-agar, colony formation, flow cytometry and tumor formation in nude mice. CDK2 inhibitor and paclitaxel were used in testing combination therapy in vitro and in vivo. Results: ACTL6A bound MYC to suppress glycogen synthase kinase 3 beta (GSK3β)-induced phosphorylation on MYC T58, which inhibited ubiquitination of MYC and stabilized it. Moreover, ACTL6A promoted the recruitment of MYC and histone acetyltransferase KAT5 on CDK2 promoters, leading to hyperactivation of CDK2 transcription. ACTL6A overexpression promoted, while silencing ACTL6A suppressed cell proliferation and tumor growth in TNBC cells in vitro and in vivo, which was dependent on MYC signaling. Furthermore, co-therapy with paclitaxel and CDK2 inhibitor showed synergistic effects in tumor suppression. Notably, ACTL6A/MYC/CDK2 axis was specifically up-regulated in TNBC and high expression of ACTL6A was correlated to shorter survival in patients with TNBC. Conclusions: These findings reveal a novel mechanism by which ACTL6A prolongs the retention of MYC in TNBC and suggest that pharmacological targeting ACTL6A/MYC/CDK2 axis might have therapeutic potential in patients with TNBC.Keywords
Funding Information
- National Natural Science Foundation of China (81772826, 81972459, 81672957, 82003052)
- National Key Research and Development Program of China (2020YFA0509400)
- Natural Science Foundation of Guangdong Province (2020A1515010260, 2019A1515011449, 2017A030313761)
- Science and Technology Innovation Committee of Shenzhen Municipality (JCYJ20160428180814307)
- Fundamental Research Funds for the Central Universities (18ykpy28)
- Outstanding Young Talents Program from The Eighth Hospital of Sun Yat-sen University (2017001)
- Postdoctoral Research Foundation of China (2019M663290)
This publication has 50 references indexed in Scilit:
- ACTL6a Enforces the Epidermal Progenitor State by Suppressing SWI/SNF-Dependent Induction of KLF4Cell Stem Cell, 2013
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionThe Journal of Experimental Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Myc’s broad reachGenes & Development, 2008
- The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004Cancer, 2008
- Triple negative tumours: a critical reviewHistopathology, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005